We are live on ! Find out more
PAS

Point72 Asia (Singapore) Portfolio holdings

AUM $646M
1-Year Est. Return 35.24%
This Fund
S&P 500
This Quarter Est. Return
+16.23%
1 Year Est. Return
+35.24%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$646M
AUM Growth
+$82.8M
Cap. Flow
+$27.3M
Cap. Flow %
4.22%
Top 10 Hldgs %
30.39%
Holding
1,302
New
449
Increased
148
Reduced
259
Closed
438

Top Buys

Rank Stock Value
1
CYBR
CyberArk
CYBR
+$26.7M
2
AVGO icon
Broadcom
AVGO
+$21.8M
3
META icon
Meta Platforms (Facebook)
META
+$17.8M
4
NSC icon
Norfolk Southern
NSC
+$16M
5
MSFT icon
Microsoft
MSFT
+$13.8M

Sector Composition

Rank Sector Weight
1 Technology 34.45%
2 Industrials 13.75%
3 Communication Services 10.75%
4 Healthcare 9.41%
5 Financials 9.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALTO icon
651
Alto Ingredients
ALTO
$360M
$28K ﹤0.01%
25,886
IRT icon
652
Independence Realty Trust
IRT
$3.92B
$27.8K ﹤0.01%
+1,699
New +$29.4K
CTS icon
653
CTS Corp
CTS
$1.72B
$27.8K ﹤0.01%
696
-7,381
-91% -$306K
AMTX icon
654
Aemetis
AMTX
$119M
$27.7K ﹤0.01%
12,324
-12,324
-50% -$32.7K
ASB icon
655
Associated Banc-Corp
ASB
$5.81B
$27.6K ﹤0.01%
1,072
-5,301
-83% -$136K
WSBF icon
656
Waterstone Financial
WSBF
$362M
$27.5K ﹤0.01%
+1,764
New +$25.3K
ABOS icon
657
Acumen Pharmaceuticals
ABOS
$154M
$27.4K ﹤0.01%
16,044
-5,296
-25% -$7.33K
SMBK icon
658
SmartFinancial
SMBK
$855M
$27.1K ﹤0.01%
758
-177
-19% -$6.33K
STRO icon
659
Sutro Biopharma
STRO
$379M
$26.9K ﹤0.01%
3,103
-3,004
-49% -$25.6K
MMS icon
660
Maximus
MMS
$3.14B
$26.8K ﹤0.01%
293
-6,016
-95% -$487K
TCRX icon
661
TScan Therapeutics
TCRX
$51.9M
$26.5K ﹤0.01%
14,535
-14,535
-50% -$25.7K
MGNI icon
662
Magnite
MGNI
$2.65B
$26.4K ﹤0.01%
+1,210
New +$28.6K
NAVI icon
663
Navient
NAVI
$774M
$26.1K ﹤0.01%
+1,986
New +$27K
ULBI icon
664
Ultralife
ULBI
$88.3M
$25.9K ﹤0.01%
+3,804
New +$28.8K
MSBI icon
665
Midland States Bancorp
MSBI
$669M
$25.9K ﹤0.01%
1,513
+267
+21% +$4.8K
HOWL icon
666
Werewolf Therapeutics
HOWL
$20.8M
$25.6K ﹤0.01%
13,016
-7,110
-35% -$9.73K
ALXO icon
667
ALX Oncology
ALXO
$273M
$25.4K ﹤0.01%
13,907
-13,802
-50% -$12K
MLTX icon
668
MoonLake Immunotherapeutics
MLTX
$1.59B
$25.3K ﹤0.01%
+3,535
New +$184K
DXLG icon
669
Destination XL Group
DXLG
$34.7M
$25.1K ﹤0.01%
19,144
-344
-2% -$451
OVID icon
670
Ovid Therapeutics
OVID
$435M
$24.9K ﹤0.01%
19,173
-19,209
-50% -$16.6K
EIG icon
671
Employers Holdings
EIG
$908M
$24.8K ﹤0.01%
584
-1,273
-69% -$55.4K
EVCM icon
672
EverCommerce
EVCM
$2.05B
$24.6K ﹤0.01%
+2,211
New +$24.7K
OBK icon
673
Origin Bancorp
OBK
$1.66B
$24.6K ﹤0.01%
+712
New +$26.4K
MRVI icon
674
Maravai LifeSciences
MRVI
$997M
$24.5K ﹤0.01%
+8,522
New +$21.8K
RMR icon
675
The RMR Group
RMR
$342M
$24.3K ﹤0.01%
1,546
-5,320
-77% -$88.9K

Similar funds

Point72 Asia (Singapore)'s Q3 2025 Portfolio in Review

As of Q3 2025, Point72 Asia (Singapore) held 1,302 positions worth $646M, up 15% from $563M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Point72 Asia (Singapore) deployed $27.3M of net new capital in Q3 2025, opening 449 new positions and adding to 148 existing holdings. Its largest new stake was CyberArk: 62,086 shares worth $30M.

By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 16% a quarter earlier, followed by Industrials and Communication Services.

On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $15.1M trimmed.

  • Point72 Asia (Singapore)'s largest Q3 2025 buy was CyberArk: 62,086 shares worth $30M.
  • Point72 Asia (Singapore) added most to Meta Platforms (Facebook) in Q3 2025, an estimated $17.8M increase.
  • Point72 Asia (Singapore)'s biggest Q3 2025 reduction was Alphabet (Google) Class C, cutting an estimated $15.1M.
  • Point72 Asia (Singapore) fully exited Advanced Micro Devices in Q3 2025, selling an estimated $12.9M.
  • Point72 Asia (Singapore)'s ten largest holdings make up 30% of its $646M portfolio in Q3 2025.
  • Point72 Asia (Singapore) opened 449 new positions and closed 438 in Q3 2025.
  • Point72 Asia (Singapore)'s portfolio value rose 15% quarter-over-quarter to $646M.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.